Most Recent
Finish maker Reckitt Benckiser has lost its bid to trademark the shape of its dishwashing capsule, with a delegate finding it was not a “wholly concocted” shape that can be distinguished from similar products by other brands.
Sandoz has accused Amgen of 'dragging the chain' as the Swiss biotech continues to mull whether to launch infringement proceedings over six patents for its Prolia and Xgeve bone disease biologics.
Generic drug maker Sandoz wants to shield information turned up by preliminary discovery orders from the eyes of Amgen patent attorneys in a spat over cheap versions of Amgen's bone disease drugs, and says if they view the material they should be barred from prosecuting future related patents.
Biopharmaceutical company Amgen has lodged proceedings against generic maker Sandoz, calling for documents related to regulatory approval of a generic version of its top-selling bone disease treatments.
Drug giant Sanofi has failed in its appeal of a decision granting applications by biopharmaceutical company Amgen for patents covering the cholesterol-lowering treatment Repatha.
TCT Group has won orders revoking two patents for hinges held by Polaris IP as well as indemnity costs, with a judge finding the patentee made “unjustifiable” threats of infringement against TCT over its own brand of soft-close glass hinges.
French drug giant Sanofi has appealed a decision giving American biopharmaceutical company Amgen the go-ahead for its patents for a cholesterol-lowering antibody that could be used to treat heart disease, diabetes, stroke and Alzheimer’s.
A judge has given Generic Health more time to file its evidence in a multimillion-dollar dispute with drug makers Otsuka and Bristol-Myers Squibbs over the delayed launch of generic versions of their antipsychotic drug Abilify, but warned there had to be a cut-off point for preparing the decade-long dispute for trial.
The companies behind the top selling Abilify medication have lost their latest bid for documents from the Commonwealth in a multimillion dollar dispute over the delayed listing of generic versions of their drug, with a judge saying the material could be only "of the most marginal relevance".